I agree. I've been saying that this one will race ahead as the program unfolds. There's been a lull over Xmas but the price has now been firming steadily. look for a breakout.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%